Skip to main content
. 2020 Jul 17;21(14):5064. doi: 10.3390/ijms21145064

Table 1.

Structures, binding type and bioactivities of Δ9-THC, CBD, Δ9-THCP and CBDP.

Phytocannabinoids Binding Type/CB Ki (nM)/CB EC50/IC50 (nM)/CB Bioactivity
Inline graphic
(a)
Δ9-THC		 Partial agonist/CB1, CB2 5.00~80.0/CB1
1.70~75.0/CB2 [14]		 13.0~87.0/CB1
41.8, 61.0/CB2 [14]		 Analgesic,
antiemetic,
orexigenic [53];
relief from muscle spasms/spasticity in multiple sclerosis [61]
Inline graphic
(b)
CBD		 Antagonist/inverse agonist, negative allosteric modulator/CB1
Partial agonist/CB2		 73.0~>10,000/CB1
370~>10,000/CB2 [14]		 3860/CB1
503, 2270/CB2 [14]		 Anti-inflammatory,
anti-nociceptive,
anti-oxidant,
anti-ischemic, neuroprotective, immunosuppressive [62];
anxiolytic [43,62]
Inline graphic
(c)
Δ9-THCP		 Agonist/CB1, CB2 1.20/CB1
6.20/CB2 [39]		 NA Analgesic [39]
Inline graphic
(d)
CBDP		 NA NA NA NA

Ki: binding constant; EC50: half-maximal effective concentration; IC50: half-maximal inhibitory concentration; NA: not available.